Evidence & regulatory context
- Mechanism
- No ChEMBL record under the NSC identifier (compound_search on 'NSC194598' returned zero hits); the underlying chemical name was not given in the source record so no synonym search was possible. No ClinicalTrials.gov records.
- Target
- Not recorded
- Injury models
- Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseRadiationC57BL/6Male and femaleIntraperitoneal injection, compound dissolved in 0.1 mL of 40% (2-hydroxypropyl)-beta-cyclodextrinImmediately before irradiation
Model: Whole-body gamma irradiation at 8 Gy
A single dose of NSC194598 given immediately before 8 Gy gamma irradiation increased survival; the compound inhibited p53 DNA binding and target gene induction when p53 was stabilised by irradiation or chemotherapy.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
